Zimmer Biomet to Release Q3 Earnings on November 5, 2025

Zimmer Biomet Holdings, Inc. is set to announce its third-quarter earnings for fiscal year 2025 on November 5, 2025, before the market opens. Analysts anticipate the company will report earnings of $1.87 per share, alongside revenues estimated at $2.0089 billion. This announcement is highly anticipated as Zimmer Biomet has previously set its fiscal year 2025 guidance between $8.100 and $8.300 EPS.

Investors and analysts are encouraged to explore the company’s earnings overview page for the latest information regarding the earnings call scheduled for 8:30 AM ET on that day. In its last earnings report on August 7, 2025, Zimmer Biomet exceeded analyst expectations with earnings of $2.07 per share, surpassing projections of $1.98 by $0.09. The company reported revenues of $2.08 billion, compared to forecasts of $2.06 billion, representing a year-over-year revenue increase of 7.0%.

Stock Performance and Dividend Declaration

As of the upcoming earnings announcement, shares of Zimmer Biomet opened at $101.18. The company has a market capitalization of $20.04 billion, a price-to-earnings (P/E) ratio of 24.62, and a beta of 0.67. Zimmer Biomet also declared a quarterly dividend of $0.24, which will be paid on October 31, 2025, to shareholders of record as of September 30, 2025. This translates to an annualized dividend of $0.96 and a yield of 0.9%.

Analysts remain optimistic regarding the company’s future performance. Research reports have varied in their outlook, with Evercore ISI reducing its price target on Zimmer Biomet from $106.00 to $104.00, maintaining an “in-line” rating. Conversely, Royal Bank of Canada has set a target price of $111.00, indicating a positive outlook for the stock.

Insider Transactions and Institutional Investments

In recent transactions, Lori Winkler, Senior Vice President of Zimmer Biomet, sold 1,500 shares on September 8, 2025, at an average price of $104.15, amounting to a total of $156,225. Following this sale, she holds 6,833 shares of the company, valued at approximately $711,656.95, reflecting an 18.00% decrease in her ownership.

Institutional investors have shown considerable interest in Zimmer Biomet, with their ownership currently standing at 88.89% of the company’s stock. Recent additions include Orion Portfolio Solutions LLC, which purchased a new stake worth approximately $426,000, and State of Wyoming, acquiring a position valued around $124,000.

Zimmer Biomet, based in the United States, operates globally in the medical technology sector, specializing in orthopedic reconstructive products. The company’s offerings include knee and hip implants, trauma products, and solutions for craniofacial reconstruction. As it prepares to release its earnings report, all eyes will be on how it navigates the competitive landscape and adjusts its strategies for sustained growth.